B. Riley Upgrades Cue Biopharma to Buy on Allergy Drug Outlook

B. Riley has upgraded Cue Biopharma (CUE) to a Buy rating, citing the promising outlook for its upcoming allergy medication. The analyst highlighted the drug’s potential to capture a sizable segment of the allergy treatment market, and noted that Cue’s strong pipeline and recent clinical data support the bullish stance. The rating reflects confidence in the company’s ability to monetize the new therapy and expand its market presence.